A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity

MLA

Franciscary Pi-Estopinan, et al. “A Randomized, Double-Blind Phase I Clinical Trial of Two Recombinant Dimeric RBD COVID-19 Vaccine Candidates: Safety, Reactogenicity and Immunogenicity.” Vaccine, vol. 40, Mar. 2022, pp. 2068–75. EBSCOhost, https://doi.org/10.1016/j.vaccine.2022.02.029.

APA

Franciscary Pi-Estopinan, Jorman Rubino-Moreno, Mayte Amoroto-Roig, Maria Teresa Perez-Guevara, Yury Valdés-Balbín, Laura M. Rodríguez-Noda, Marisel Martinez-Perez, Meiby de la Caridad Rodriguez-Gonzalez, Carmen M Valenzuela-Silva, Dagmar García-Rivera, Rolando Ochoa-Azze, Maura Tamayo-Rodriguez, Raul Gonzalez-Mugica, Vicente Verez-Bencomo, Yanet Chappi-Estevez, Yanet Climent-Ruiz, Belinda Sanchez-Ramirez, Beatriz Paredes-Moreno, Anamary Suarez-Batista, … Carlos A. González-Delgado. (2022). A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity. Vaccine, 40, 2068–2075. https://doi.org/10.1016/j.vaccine.2022.02.029

Chicago

Franciscary Pi-Estopinan, Jorman Rubino-Moreno, Mayte Amoroto-Roig, Maria Teresa Perez-Guevara, Yury Valdés-Balbín, Laura M. Rodríguez-Noda, Marisel Martinez-Perez, et al. 2022. “A Randomized, Double-Blind Phase I Clinical Trial of Two Recombinant Dimeric RBD COVID-19 Vaccine Candidates: Safety, Reactogenicity and Immunogenicity.” Vaccine 40 (March): 2068–75. doi:10.1016/j.vaccine.2022.02.029.